OMSÄTTNING OCH AKTIEKURS
I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.
- Omsättning
- Aktuell Kurs
- Utvecklingen i dag
Pressreleaser | 26 Sep 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Mangold Insight publishes…
What can you tell us about Biosergens main candidate BSG005?Can you tell us about the competitors and market opportunities for BSG005?What will the proceeds from the rights issue be used…
Pressreleaser | 22 Sep 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Members of the board of…
Subscription and underwriting commitmentsThe Rights Issue is covered to approximately 33 percent through subscription commitments and to approximately 37 percent through underwriting commitments. In total, 70 percent of the Rights…
Pressreleaser | 15 Sep 2022 | Biosergen
Läs hela nyheten
Biosergen AB: The subscription period in…
The Rights Issue in summary: Subscription period: September 15, 2022 – September 29, 2022. Trade in unit rights: September 15, 2022 – September 26, 2022. Preferred rights: For every one…
Pressreleaser | 8 Sep 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen moves into the…
The Safety Review Committee for this study has reviewed all the available safety and PK data and concluded that the dose level achieved did not provoke any serious adverse event…
Pressreleaser | 2 Sep 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen's Board of…
Summary Upon full subscription, the Rights Issue provides Biosergen with approximately SEK 60.2 million before issuing costs. In the event of full subscription and full exercise of all warrants of…
Pressreleaser | 31 Aug 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen publishes…
Summary of the Interim Report for Q2 2022 2022 2021 2022 2021 2021TSEK April-June April-June Jan-June Jan-June Jan-Dec Consolidated group 1.409 2.001 2.726 2.001 11.570revenueConsolidated group -7.963 -9.493 -12.981 -17.798…
Pressreleaser | 31 Aug 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen receives a loan…
The Loan is issued by Biosergens largest shareholder Östersjöstiftelsen (the ”Lender”). The main terms of the Loan are as follows: The Lender agrees to lend to the Company a maximum…
Pressreleaser | 26 Aug 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen completes the…
BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and…
Pressreleaser | 11 Jul 2022 | Biosergen
Läs hela nyheten
Biosergen AB: 3P Biopharmaceuticals and…
July 11, 2022, 3P Biopharmaceuticals ( https://3pbio.com/ ) (3P), a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) has completed the manufacture of BSG005 biomass…
Pressreleaser | 30 Jun 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen successfully…
BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and…
Kommande händelser
Ta del av analyser, event och erbjudanden
Prenumerera på nyheter från Erik Penser Bank.
Genom att skicka in din mailadress godkänner du vår personuppgiftspolicy*
Dela nyheter & rapporter från EP Access